Published phase 1 findings support the promising efficacy and tolerability of anito-cel in relapsed/refractory multiple myeloma, explains lead author Matthew Frigault, MD.
|Videos|April 1, 2019
Asymptomatic Relapsed Multiple Myeloma
Asymptomatic Relapsed Multiple Myeloma
Advertisement
Case: 56-Year-Old Man With Asymptomatic Relapsed Multiple Myeloma
History:
- In 2015, at the age of 53, an African-American man was diagnosed with multiple myeloma; R-ISS stage I
- Patient was treated with bortezomib + lenalidomide + dexamethasone (VRd) for 4 cycles, followed by ASCT
- Patient achieved a VGPR
- Received lenalidomide maintenance for 2 years
September 2018
- On routine follow-up, no clinical symptoms observed
- Imaging: stable disease
- Laboratory results:
- Hb, 11.3 g/dL
- Ca2+9.2 mg/dL
- Creatinine, 0.8 mg/dL
- M-protein:
- June: 1.2 g/dL
- July: 1.4 g/dL
- August: 1.7 g/dL
- Cytogenetics/FISH: no adverse cytogenetics
- ECOG PS: 0
- Patient was started on ixazomib + lenalidomide + dexamethasone (IRd)
Advertisement
Related to this article
In the phase 3 EXCALIBER-RRMM trial, iberdomide plus daratumumab and dexamethasone doubled MRD-negative complete response rates over standard therapy in relapsed myeloma.
Closing sessions at IMS 2026 featured MRD-guided treatment strategies, real-world CAR T-cell data, and mixed results on cilta-cel neurotoxicity prevention in myeloma.
Etentamig significantly improved response and survival over standard therapy in the phase 3 CERVINO trial, headlining day 3 of IMS 2026 myeloma coverage.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
Half of patients who stopped MRD-guided maintenance in GEM2014MAIN remained progression-free at 7 years, as IMS 2026 also featured DREAMM-9, MIDAS, and novel bispecific data.
A new IMS/IMWG consensus definition requires 5 years of treatment-free, MRD-negative remission before multiple myeloma can be called cured.
Mezigdomide plus elranatamab yielded a 100% ORR in MELT-MM, as other IMS 2026 abstracts covered cevostamab, anito-cel vs cilta-cel, and linvoseltamab in HR-SMM.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
2
Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices
3
FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer
4
Frontline CAR T and Bispecific Antibodies Are the Next Frontier in Myeloma
5